Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 658-663

  Bacci, G ^a   Ferrari, S ^a   Delepine, N ^a   Bertoni, F ^a   Picci, P ^a   Mercuri, M ^a   Bacchini, P ^a   Brach Del Prever, A ^a   Tienghi, A ^a   Comandone, A ^a   Campanacci, M ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031943038     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.658     Document Type: Article

References (28)

1. Rosen G, Marcove RC, Caparros B, et al: Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163-2177, 1979
2. Jurgens H, Kosloff C, Niremberg A, et al: Prognostic factors in the response of primary osteogenic sarcoma to the preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monograph 56:221-226, 1981
3. Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-1230, 1982
4. Winkler K, Beron G, Kotz R, et al: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 2:617-624, 1984
5. Delepine N, Delepine G, Jasmin C, et al: Prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 42:257-262, 1988
6. Winkler K, Beron G, Delling G, et al: Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329-337, 1988
7. Saeter G, Alvegrad TA, Elomaa I, et al: Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 9:1766-1775, 1991
8. Benjamin RS, Chawla SP, Carrasco CH, et al: Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum. Ann Oncol 3:3-4, 1992 (suppl 2)
9. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering Experience. J Clin Oncol 10:5-15, 1992
10. Gobel V, Jurghens H, Etspuler G, et al: Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescent. Cancer Res Clin Oncol 113:187-191, 1987
11. Bacci G, Picci P, Ferrari S, et al: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremity. Results in 164 patients preoperatively treated with high doses of methotrexate, followed by cisplatin and doxorubicin. Cancer 72:1216-1226, 1993
12. Bacci G, Picci P, Ferrari S, et al: Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: Results of two sequential studies. J Chemother 5:237-246, 1993
13. Bacci G, Ferrari S, Ferraro A, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities. Ital J Orthop Traumatol 20:311-329, 1994
14. Rosen G, Nirenberg G: Chemotherapy for osteogenic sarcoma: An investigative method, not a recipe. Cancer Treat Rep 4:11-17, 1982
15. Picci P, Bacci G, Campanacci M, et al: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56:1515-1521, 1985
16. Huvos AG, Rosen G, Marcove RC: Pathologic aspects in 20 patients after treatment with chemotherapy, en block resection, and prosthetic bone replacement. Arch Pathol Lab Med 101:14-18, 1977
17. Ferrari S, Sassoli V, Orlandi M, et al: Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 5:135-141, 1993
18. Ayala AG, Raymond KR, Jaffe N: The pathologist's role in diagnosis and treatment of osteosarcoma in children: Controversies, current status and projections. Hum Pathol 15:258-266, 1984
19. Salzer-Kuntschik M, Brand G, Delling G: Bestimmung des morphologischen Regressiongrades nach Chemotherapie bei malignen Knochentumoren. Pathologie 4:135-141, 1983
20. Winkler K, Bielack S, Delling G, et al: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high dose methotrexate and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 66:1703-1710, 1990
21. Dahlin DC, Unni KK: Osteosarcoma of bone and its important recognizable varieties. Am Surg Pathol 1:61-68, 1977
22. Chuang VP, Benjamin R, Jaffe N: Radiographic and angiographic changes in osteosarcoma after intraarterial chemotherapy. J Radiol 139:1065-1069, 1982
23. Smith J, Heelan RT, Huvos AG, et al: Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiology 143:355-360, 1982
24. Sommer HJ, Riebel T, Winkler K, et al: A comparison of radiological and histological findings in osteosarcoma following preoperative chemotherapy. Fortschr Roentgenstr 143:74-83, 1983
25. Mail JT, Cohen MD, Mirkin LD: Response of osteosarcoma to preoperative intravenous high dose methorexate chemotherapy: CT evaluation. Am J Radiol 144:89-93, 1985
26. Shiroda A, Jaffe N, Wallace A, et al: Computed tomography of osteosarcoma after intraarterial chemotherapy. Am J Radiol 144:95-99, 1985
27. Lechner G, Salzer-Kuntschick M, Kumpam V, et al: Angiographic-pathologic comparison in osteosarcoma after presurgical chemotherapy. J Cancer Res Clin Oncol 106:51-54, 1983 (suppl 1)
28. Delepine N, Desbois JC, Delepine G, et al: Individualisation de posologie de methotrexate haute dose par le dosage des concentrations plasmatique interet therapeutique dans le sarcoma osteogenique. Bull Cancer 76:913-918, 1989